Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 9, 2003, Pages 1955-1958

  Abendschein, D R ^a   Baum, P K ^a   Lightand, D R ^b   Morser, J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Berlex Biosciences   (United States)

Author keywords

Factor Xa; Vascular injury; Venous thrombosis

Indexed keywords

AMIDINE; BLOOD CLOTTING FACTOR 10A; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; PYRIDINE DERIVATIVE;

ANIMAL; ARTICLE; BALLOON DILATATION; BLOOD CLOTTING TEST; CAVA VEIN; DOSE RESPONSE; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; INJURY; PATHOLOGY; RABBIT; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

AMIDINES; ANIMALS; BALLOON DILATATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FACTOR XA; PYRIDINES; RABBITS; THROMBOLYTIC THERAPY; VENAE CAVAE; VENOUS THROMBOSIS;

EID: 2442429699     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00336.x     Document Type: Article

References (16)

1. Heit JA. Low-molecular-weight heparin: the optimal duration of pro phylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res 2001; 101: V163-V173.
2. Ledere JR, Geerts WH, Desjardins L, Laflamme GH, l'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124: 619-26.
3. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R (Ardeparin Arthroplasty Study Group). Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replace ment surgery: a double-blind, dose-ranging study. Thromb Haemost 1997; 77: 32-8.
4. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
5. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.
6. Sullivan M, Morser J, Light D, Guilford W, Vergona R, Herrmann M, White K, Phillips G, Davey D, Morrissey M, Fredrich M, Baldus B. The efficacy and safety of BX-807834, a potent, selective factor Xa inhibitor, in animal models. FASEB J 1998; 12: A719(Abstract).
7. Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, Light DR. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol 2000; 35: 796-805.
8. Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Therap 2001; 296: 572-7.
9. Baum PK, Martin D, Abendschein D. A preparation to study simulta neous arterial and venous thrombus formation in rabbits. J Invest Surg 2001; 14: 153-60.
10. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van der Meer J, Piovella F, Raskob G, Gent M. Dose-response study of recombinant factor Vila/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
11. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal sur face of balloon-injured aortas in rabbits. Circulation 1995; 92: 3323-30.
12. Wessler S. Thrombosis in the presence of vascular stasis. Am J Med 1962; 33: 648-66.
13. Reyes I, Mussoni L, Donati BM, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-74.
14. Vogel GMT, Meuleman DG, Bourdondien FGM, Hobbelen PMJ. Com parison of two experimental thrombosis models in rats effects of four glycosaminoglycans. Thromb Res 1989; 54: 399 4-10.
15. Rebello SS, Miller BV, Basler GC, Lucchesi BR. CVS-1123, a direct thro mbin inhibitor, prevents occlusive arterial and venous thrombosis in a can ine model of vascular injury. J Cardiovasc Pharmacol 1997; 29: 240-9.
16. Rebello SS, Blank HW, Rote WE, Vlasuk GP, Lucchesi BR. Antith rombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmcol Exp Therap 1997; 283: 91-9.